

**HIGHLIGHTS OF PRESCRIBING INFORMATION**

These highlights do not include all the information needed to use ABILIFY safely and effectively. See full prescribing information for ABILIFY.

ABILIFY® (aripiprazole) Tablets  
 ABILIFY DISCMELT® (aripiprazole) Orally Disintegrating Tablets  
 ABILIFY® (aripiprazole) Oral Solution  
 ABILIFY® (aripiprazole) Injection FOR INTRAMUSCULAR USE ONLY  
 Initial U.S. Approval: 2002

**WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS and SUICIDAL THOUGHTS AND BEHAVIORS WITH ANTIDEPRESSANT DRUGS**

See full prescribing information for complete boxed warning.

- Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. ABILIFY is not approved for the treatment of patients with dementia-related psychosis. (5.1)
- Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants. Monitor for worsening and emergence of suicidal thoughts and behaviors. (5.3)

----- RECENT MAJOR CHANGES -----

Warnings and Precautions, Pathological Gambling and Other Compulsive Behaviors (5.7) 08/2016  
 Warnings and Precautions, Falls (5.9) 02/2017

----- INDICATIONS AND USAGE -----

ABILIFY is an atypical antipsychotic. The oral formulations are indicated for:

- Schizophrenia (14.1)
- Acute Treatment of Manic and Mixed Episodes associated with Bipolar I (14.2)
- Adjunctive Treatment of Major Depressive Disorder (14.3)
- Irritability Associated with Autistic Disorder (14.4)
- Treatment of Tourette’s disorder (14.5)

The injection is indicated for:

- Agitation associated with schizophrenia or bipolar mania (14.6)

----- DOSAGE AND ADMINISTRATION -----

	Initial Dose	Recommended Dose	Maximum Dose
Schizophrenia – adults (2.1)	10-15 mg/day	10-15 mg/day	30 mg/day
Schizophrenia – adolescents (2.1)	2 mg/day	10 mg/day	30 mg/day
Bipolar mania – adults: monotherapy (2.2)	15 mg/day	15 mg/day	30 mg/day
Bipolar mania – adults: adjunct to lithium or valproate (2.2)	10-15 mg/day	15 mg/day	30 mg/day
Bipolar mania – pediatric patients: monotherapy or as an adjunct to lithium or valproate (2.2)	2 mg/day	10 mg/day	30 mg/day
Major Depressive Disorder – Adults adjunct to antidepressants (2.3)	2-5 mg/day	5-10 mg/day	15 mg/day
Irritability associated with autistic disorder – pediatric patients (2.4)	2 mg/day	5-10 mg/day	15 mg/day
Tourette’s disorder (2.5)	Patients < 50 kg	5 mg/day	10 mg/day
	Patients ≥ 50 kg	2 mg/day	20 mg/day
Agitation associated with schizophrenia or bipolar mania – adults (2.6)	9.75 mg /1.3 mL injected IM		30 mg/day injected IM

- Oral formulations: Administer once daily without regard to meals (2)
- IM injection: Wait at least 2 hours between doses. Maximum daily dose 30 mg (2.5)
- Known CYP2D6 poor metabolizers: Half of the usual dose (2.7)

----- DOSAGE FORMS AND STRENGTHS -----

Tablets: 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg, 120 mg (2)

- Oral Solution: 1 mg/mL (3)
- Injection: 9.75 mg/1.3 mL single-dose vial (3)

----- CONTRAINDICATIONS -----

- Known hypersensitivity to ABILIFY (4)

----- WARNINGS AND PRECAUTIONS -----

- Cerebrovascular Adverse Reactions in Elderly Patients with Dementia-Related Psychosis:** Increased incidence of cerebrovascular adverse reactions (e.g., stroke, transient ischemic attack, including fatalities) (5.2)
- Neuroleptic Malignant Syndrome:** Manage with immediate discontinuation and close monitoring (5.4)
- Tardive Dyskinesia:** Discontinue if clinically appropriate (5.5)
- Metabolic Changes:** Atypical antipsychotic drugs have been associated with metabolic changes that include hyperglycemia/diabetes mellitus, dyslipidemia, and body weight gain (5.6)
  - Hyperglycemia/Diabetes Mellitus:** Monitor glucose regularly in patients with and at risk for diabetes (5.6)
  - Dyslipidemia:** Undesirable alterations in lipid levels have been observed in patients treated with atypical antipsychotics (5.6)
  - Weight Gain:** Weight gain has been observed with atypical antipsychotic use. Monitor weight (5.6)
- Pathological Gambling and Other Compulsive Behaviors:** Consider dose reduction or discontinuation (5.7)
- Orthostatic Hypotension:** Monitor heart rate and blood pressure and warn patients with known cardiovascular or cerebrovascular disease, and risk of dehydration or syncope (5.8)
- Leukopenia, Neutropenia, and Agranulocytosis:** have been reported with antipsychotics including ABILIFY. Patients with a history of a clinically significant low white blood cell count (WBC) or a drug-induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and discontinuation of ABILIFY should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors (5.10)
- Seizures/Convulsions:** Use cautiously in patients with a history of seizures or with conditions that lower the seizure threshold (5.11)
- Potential for Cognitive and Motor Impairment:** Use caution when operating machinery (5.12)
- Suicide:** The possibility of a suicide attempt is inherent in schizophrenia and bipolar disorder. Closely supervise high-risk patients (5.14)

----- ADVERSE REACTIONS -----

Commonly observed adverse reactions (incidence ≥5% and at least twice that for placebo) were (6.1):

- Adult patients with schizophrenia: akathisia
- Pediatric patients (13 to 17 years) with schizophrenia: extrapyramidal disorder, somnolence, and tremor
- Adult patients (monotherapy) with bipolar mania: akathisia, sedation, restlessness, tremor, and extrapyramidal disorder
- Adult patients (adjunctive therapy with lithium or valproate) with bipolar mania: akathisia, insomnia, and extrapyramidal disorder
- Pediatric patients (10 to 17 years) with bipolar mania: somnolence, extrapyramidal disorder, fatigue, nausea, akathisia, blurred vision, salivary hypersecretion, and dizziness
- Adult patients with major depressive disorder (adjunctive treatment to antidepressant therapy): akathisia, restlessness, insomnia, constipation, fatigue, and blurred vision
- Pediatric patients (6 to 17 years) with autistic disorder: sedation, fatigue, vomiting, somnolence, tremor, pyrexia, drooling, decreased appetite, salivary hypersecretion, extrapyramidal disorder, and lethargy
- Pediatric patients (6 to 18 years) with Tourette’s disorder: sedation, somnolence, nausea, headache, nasopharyngitis, fatigue, increased appetite
- Adult patients with agitation associated with schizophrenia or bipolar mania: nausea

To report SUSPECTED ADVERSE REACTIONS, contact Bristol-Myers Squibb at 1-800-721-5072 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

----- DRUG INTERACTIONS -----

Dosage adjustment due to drug interactions (7.1):

Factors	Dosage Adjustments for ABILIFY
---------	--------------------------------

Known CYP2D6 Poor Metabolizers and strong CYP3A4 inhibitors	Administer a quarter of usual dose
Strong CYP2D6 or CYP3A4 inhibitors	Administer half of usual dose
Strong CYP2D6 and CYP3A4 inhibitors	Administer a quarter of usual dose
Strong CYP3A4 inducers	Double usual dose over 1 to 2 weeks

- *Nursing Mothers:* Discontinue drug or nursing, taking into consideration importance of drug to the mother (8.3)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: 02/2017

----- USE IN SPECIFIC POPULATIONS -----

- *Pregnancy:* May cause extrapyramidal and/or withdrawal symptoms in neonates with third trimester exposure (8.1)

**FULL PRESCRIBING INFORMATION: CONTENTS\***

**WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS and SUICIDAL THOUGHTS AND BEHAVIORS WITH ANTIDEPRESSANT DRUGS**

**1 INDICATIONS AND USAGE**

**2 DOSAGE AND ADMINISTRATION**

- 2.1 Schizophrenia
- 2.2 Bipolar I Disorder
- 2.3 Adjunctive Treatment of Major Depressive Disorder
- 2.4 Irritability Associated with Autistic Disorder
- 2.5 Tourette's Disorder
- 2.6 Agitation Associated with Schizophrenia or Bipolar Mania (Intramuscular Injection)
- 2.7 Dosage Adjustments for Cytochrome P450 Considerations
- 2.8 Dosing of Oral Solution
- 2.9 Dosing of Orally Disintegrating Tablets

**3 DOSAGE FORMS AND STRENGTHS**

**4 CONTRAINDICATIONS**

**5 WARNINGS AND PRECAUTIONS**

- 5.1 Increased Mortality in Elderly Patients with Dementia-Related Psychosis
- 5.2 Cerebrovascular Adverse Events, Including Stroke
- 5.3 Suicidal Thoughts and Behaviors in Children, Adolescents, and Young Adults
- 5.4 Neuroleptic Malignant Syndrome (NMS)
- 5.5 Tardive Dyskinesia
- 5.6 Metabolic Changes
- 5.7 Pathological Gambling and Other Compulsive Behaviors
- 5.8 Orthostatic Hypotension
- 5.9 Falls
- 5.10 Leukopenia, Neutropenia, and Agranulocytosis
- 5.11 Seizures/Convulsions
- 5.12 Potential for Cognitive and Motor Impairment
- 5.13 Body Temperature Regulation
- 5.14 Suicide
- 5.15 Dysphagia

**6 ADVERSE REACTIONS**

- 6.1 Clinical Trials Experience
- 6.2 Postmarketing Experience

**7 DRUG INTERACTIONS**

- 7.1 Drugs Having Clinically Important Interactions with ABILIFY
- 7.2 Drugs Having No Clinically Important Interactions with ABILIFY

**8 USE IN SPECIFIC POPULATIONS**

- 8.1 Pregnancy

- 8.2 Labor and Delivery
- 8.3 Nursing Mothers
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 CYP2D6 Poor Metabolizers
- 8.7 Hepatic and Renal Impairment
- 8.8 Other Specific Populations

**9 DRUG ABUSE AND DEPENDENCE**

- 9.1 Controlled Substance
- 9.2 Abuse
- 9.3 Dependence

**10 OVERDOSAGE**

- 10.1 Human Experience
- 10.2 Management of Overdosage

**11 DESCRIPTION**

**12 CLINICAL PHARMACOLOGY**

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

**13 NONCLINICAL TOXICOLOGY**

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
- 13.2 Animal Toxicology and/or Pharmacology

**14 CLINICAL STUDIES**

- 14.1 Schizophrenia
- 14.2 Bipolar Disorder
- 14.3 Adjunctive Treatment of Major Depressive Disorder
- 14.4 Irritability Associated with Autistic Disorder
- 14.5 Tourette's Disorder
- 14.6 Agitation Associated with Schizophrenia or Bipolar Mania

**16 HOW SUPPLIED/STORAGE AND HANDLING**

- 16.1 How Supplied
- 16.2 Storage

**17 PATIENT COUNSELING INFORMATION**

- Clinical Worsening of Depression and Suicide Risk
- Pathological Gambling and Other Compulsive Behaviors
- Use of Orally Disintegrating Tablet
- Interference with Cognitive and Motor Performance
- Nursing
- Concomitant Medication
- Heat Exposure and Dehydration
- Sugar Content
- Phenylketonurics

\*Sections or subsections omitted from the full prescribing information are not listed.

## FULL PRESCRIBING INFORMATION

### **WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS and SUICIDAL THOUGHTS AND BEHAVIORS WITH ANTIDEPRESSANT DRUGS**

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. ABILIFY is not approved for the treatment of patients with dementia-related psychosis [see [WARNINGS AND PRECAUTIONS \(5.1\)](#)].

Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older [see [WARNINGS AND PRECAUTIONS \(5.3\)](#)].

In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber [see [WARNINGS AND PRECAUTIONS \(5.3\)](#)].

## 1 INDICATIONS AND USAGE

ABILIFY Oral Tablets, Orally-Disintegrating Tablets, and Oral Solution are indicated for the treatment of:

- Schizophrenia [see [CLINICAL STUDIES \(14.1\)](#)]
- Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder [see [CLINICAL STUDIES \(14.2\)](#)]
- Adjunctive Treatment of Major Depressive Disorder [see [CLINICAL STUDIES \(14.3\)](#)]
- Irritability Associated with Autistic Disorder [see [CLINICAL STUDIES \(14.4\)](#)]
- Treatment of Tourette's Disorder [see [CLINICAL STUDIES \(14.5\)](#)]

ABILIFY Injection is indicated for the treatment of:

- Agitation associated with schizophrenia or bipolar mania [*see [CLINICAL STUDIES \(14.6\)](#)*]

## **2 DOSAGE AND ADMINISTRATION**

### **2.1 Schizophrenia**

#### **Adults**

The recommended starting and target dose for ABILIFY is 10 or 15 mg/day administered on a once-a-day schedule without regard to meals. ABILIFY has been systematically evaluated and shown to be effective in a dose range of 10 to 30 mg/day, when administered as the tablet formulation; however, doses higher than 10 or 15 mg/day were not more effective than 10 or 15 mg/day. Dosage increases should generally not be made before 2 weeks, the time needed to achieve steady-state [*see [CLINICAL STUDIES \(14.1\)](#)*].

Maintenance Treatment: Maintenance of efficacy in schizophrenia was demonstrated in a trial involving patients with schizophrenia who had been symptomatically stable on other antipsychotic medications for periods of 3 months or longer. These patients were discontinued from those medications and randomized to either ABILIFY 15 mg/day or placebo, and observed for relapse [*see [CLINICAL STUDIES \(14.1\)](#)*]. Patients should be periodically reassessed to determine the continued need for maintenance treatment.

#### **Adolescents**

The recommended target dose of ABILIFY is 10 mg/day. Aripiprazole was studied in adolescent patients 13 to 17 years of age with schizophrenia at daily doses of 10 mg and 30 mg. The starting daily dose of the tablet formulation in these patients was 2 mg, which was titrated to 5 mg after 2 days and to the target dose of 10 mg after 2 additional days. Subsequent dose increases should be administered in 5 mg increments. The 30 mg/day dose was not shown to be more efficacious than the 10 mg/day dose. ABILIFY can be administered without regard to meals [*see [CLINICAL STUDIES \(14.1\)](#)*]. Patients should be periodically reassessed to determine the need for maintenance treatment.

#### **Switching from Other Antipsychotics**

There are no systematically collected data to specifically address switching patients with schizophrenia from other antipsychotics to ABILIFY or concerning concomitant administration with other antipsychotics. While immediate discontinuation of the previous antipsychotic treatment may be acceptable for some patients with schizophrenia, more gradual discontinuation

may be most appropriate for others. In all cases, the period of overlapping antipsychotic administration should be minimized.

## **2.2 Bipolar I Disorder**

### **Acute Treatment of Manic and Mixed Episodes**

Adults: The recommended starting dose in adults is 15 mg given once daily as monotherapy and 10 mg to 15 mg given once daily as adjunctive therapy with lithium or valproate. ABILIFY can be given without regard to meals. The recommended target dose of ABILIFY is 15 mg/day, as monotherapy or as adjunctive therapy with lithium or valproate. The dose may be increased to 30 mg/day based on clinical response. The safety of doses above 30 mg/day has not been evaluated in clinical trials.

Pediatrics: The recommended starting dose in pediatric patients (10 to 17 years) as monotherapy is 2 mg/day, with titration to 5 mg/day after 2 days, and a target dose of 10 mg/day after 2 additional days. Recommended dosing as adjunctive therapy to lithium or valproate is the same. Subsequent dose increases, if needed, should be administered in 5 mg/day increments. ABILIFY can be given without regard to meals [*see* [CLINICAL STUDIES \(14.2\)](#)].

## **2.3 Adjunctive Treatment of Major Depressive Disorder**

### **Adults**

The recommended starting dose for ABILIFY as adjunctive treatment for patients already taking an antidepressant is 2 to 5 mg/day. The recommended dosage range is 2 to 15 mg/day. Dosage adjustments of up to 5 mg/day should occur gradually, at intervals of no less than 1 week [*see* [CLINICAL STUDIES \(14.3\)](#)]. Patients should be periodically reassessed to determine the continued need for maintenance treatment.

## **2.4 Irritability Associated with Autistic Disorder**

### **Pediatric Patients (6 to 17 years)**

The recommended dosage range for the treatment of pediatric patients with irritability associated with autistic disorder is 5 to 15 mg/day.

Dosing should be initiated at 2 mg/day. The dose should be increased to 5 mg/day, with subsequent increases to 10 or 15 mg/day if needed. Dose adjustments of up to 5 mg/day should occur gradually, at intervals of no less than 1 week [*see* [CLINICAL STUDIES \(14.4\)](#)]. Patients should be periodically reassessed to determine the continued need for maintenance treatment.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.